Clinical Research:
East Bay Rheumatology Medical Group conducts cutting-edge research in Rheumatoid Arthritis, Lupus, Osteoarthritis other Rheumatic and Auto Immune diseases. We work with leading Pharmaceutical Companies and all studies are regulated by the FDA and follow strict legal and ethical codes to protect the interests and welfare of patients. Our goal is to find new and improved medications and treatments that help you with your disease and provide help for others in the future.
If you are interested in one of our clinical trials, please call our Research Department at: 510-357-1040.
Enrolling Clinical Trials at East Bay Rheumatology Research Institute:
SYSTEMIC LUPUS ERYTHEMATOSUS:
PHOENYCS - A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Dapirolizumab Pegol in study participants with moderately to severely active systemic lupus erythematosus
PHOENYCS LTE - A multicenter, open-label extension study to assess the long-term safety and tolerability of Dapirolizumab Pegol treatment in study participants with systemic lupus erythematosus
GOUT:
FORWARD OL - A phase 4, open-label, multicenter, efficacy, safety, pharmacokinetics and pharmacodynamics trial of intravenous KRYSTEXXA® (pegloticase) administered every 4 weeks with co-administration of weekly doses of Methotrexate in patients with uncontrolled refractory gout
ADVANCE - A phase 4, multicenter, open-label, efficacy and safety trial of Pegloticase and Methotrexate co-administered in patient with uncontrolled gout who have previously received Pegloticase monotherapy bud did not maintain a serum uric acid response
RHEUMATOID ARTHRITIS:
BRANCH - A randomized, controlled pragmatic phase 3b/4 study of Baricitinib in patients with rheumatoid arthritis
Active Studies
SYSTEMIC LUPUS ERYTHEMATOSUS:
SLEek - A phase 2 study to investigate the safety and efficacy of Elsubrutinib and Upadacitinib given alone or in combination (ABBV-559 Combination) in subjects with moderately to severely active systemic lupus erythematosus
SLEek LTE - A phase 2, long-term extension (LTE) study with Elsubrutinib and Upadacitinib given alone or in combination (ABBV-559) in subjects with moderately to severely active systemic lupus erythematosus who have completed the M19-130 phase 2 randomized controlled trial
MEADOW - A phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06700841 in participants with active systemic lupus erythematosus
RHEUMATOID ARTHRITIS:
RA- BRIDGE - A randomized, active-controlled, parallel-group, phase 3b/4 study of Baricitinib in patients with rheumatoid arthritis
AIM- RA - A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Abbv-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs)
PSORIATIC ARTHRITIS:
SELECT PsA 1 - A phase 3, randomized, double-blind, study comparing Upadacitinib (ABT-494) to placebo and to Adalimumab in subjects with active psoriatic arthritis who have a history of inadequate response to at least one non-biologic disease modifying anti-rheumatic (DMARD)
KEEPsAke 2 - A phase 3, randomized, double-blind study comparing Risankizumab to Placebo in subjects with active psoriatic arthritis including those who have a history of inadequate response or intolerance to biologic therapy(ies)
FOREMOST - A phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Apremilast (CC-10004) in subjects with early, oligoarticular psoriatic arthritis despite initial stable treatment with either NSAIDs and/or 1 conventional synthetic DMARD
ANKYLOSING SPONDYLITIS:
INVIGORATE - A randomized, double-blind, placebo-controlled, parallel-group, phase III multicenter study intravenous Secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerability up to 52 weeks in subjects with active ankylosing spondylitis or non-radiographic axial spondyloarthritis
INVIGORATE OL – An open-label, multicenter protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment